biotech

road fork sign

Has Biocept Reached an Inflection Point?

Biocept Inc. (NASDAQ: BIOC) has seen its stock move up over 200% in the past week, only to give back about 20% in Thursday's trading. This initial jump was brought about when Biocept ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Comfortable hospital bed

Top UBS Health Care Stocks to Buy for 2015 and Beyond

As the market surges higher, investors start to get a touch more concerned about where they allocate capital. One sector that is consistently ranked as an overweight from almost every ...
Read Full Story »
Exercise fitness

Biocept Breaks Through With Columbia Study

Biocept Inc. (NASDAQ: BIOC) announced that its blood-based diagnostic, OncoCEE-BR, was used to determine hormonal status of metastatic breast cancer patients in a prospective study at Columbia University in New ...
Read Full Story »
research

Is Revlimid Becoming a Catch-All Cancer Drug?

Celgene Corp. (NASDAQ: CELG) announced that the U.S. Food and Drug Administration (FDA) expanded the existing indication for Revlimid in conjunction with dexamethasone. This would go toward treating patients that ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Pills

Why 1 Analyst Sees Over 50% Upside in Sarepta

Sarepta Therapeutics Inc. (NASDAQ: SRPT) received a favorable rating from Merrill Lynch, and as a result the stock was climbing in Tuesday’s trading session. The firm raised its rating to ...
Read Full Story »
IPO

Biotechs and Chinese E-Commerce Firm on IPO Calendar Next Week

A full dozen initial public offerings (IPOs) were listed on last week’s calendar, but by Friday only five of the scheduled deals had priced and begun trading. Two of last ...
Read Full Story »
Biotechnology word cloud

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
145922793

5 Top Credit Suisse Health Care Stock Picks to Buy for 2015

As one of the top sectors in the S&P 500 in 2014, health care has one factor that almost always makes it a reasonably safe place to invest in. The ...
Read Full Story »
Stock Split Image

Gilead Dividend and Buyback Different From Amgen’s Strategy

Most investors invest in biotech companies for their drug pipelines and endless growth potential. The problem is that eventually biotech companies can get so large that they are effectively just ...
Read Full Story »
Pills

Will Increased Competition Hurt Gilead’s Outlook?

Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter results Tuesday after the markets closed as $2.43 in earnings per share (EPS) and $7.3 billion in revenue, against Thomson Reuters consensus ...
Read Full Story »
biotech

What to Expect From Gilead Earnings

Tuesday after the markets close, Gilead Sciences Inc. (NASDAQ: GILD) will report its fourth-quarter financial results. Thomson Reuters has consensus estimates of $2.22 in earnings per share (EPS) and $6.72 ...
Read Full Story »
95992888

Did Biogen Run Too Much After Earnings?

Biogen Idec Inc. (NASDAQ: BIIB) announced its fourth-quarter financials Thursday after the markets closed. The company reported revenue of $2.6 billion, up 34% from the fourth quarter of the previous year. Revenues ...
Read Full Story »
Money background. Close-up.

Is Celgene’s Outlook Good Enough for Investors?

Celgene Corp. (NASDAQ: CELG) reported its fourth-quarter results on Thursday morning. The biotech giant did beat earnings, but investors have to weigh whether it was enough when you consider that ...
Read Full Story »